drugset / Trial / NCT02991612

Rifaximin in Patients With Gastroesophageal Variceal Bleeding

NCT02991612

Completed 80 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Timeline

Start
2016-11-25
Primary completion
2017-12-22
Completion
2018-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 400 mg